Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients
- PMID: 8135145
Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients
Abstract
SIL-2R levels mainly depend on a T lymphocyte production. The mechanisms responsible for the elevated blood concentrations of SIL-2R in advanced solid tumors are still unknown. To investigate the role played by the monocyte-macrophage system on SIL-2R release, we have evaluated serum levels of SIL-2R in 10 head and neck cancer patients during GM-CSF subcutaneous administration (3 mcg/kg/day for 11 consecutive days). Serum levels of TNF and neopterin, both produced by macrophages, were also measured. SIL-2R mean concentration significantly enhanced in response to GM-CSF, and their rise positively correlated to that in TNF and neopterin values, while lymphocyte mean number did not increase during the study. The present results represent the first in vivo demonstration that SIL-2R release is related to macrophage activation, rather than to depend only on lymphocyte proliferation.
Similar articles
-
A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.J Biol Regul Homeost Agents. 1994 Jan-Mar;8(1):32-5. J Biol Regul Homeost Agents. 1994. PMID: 7976492
-
Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.Gynecol Oncol. 1994 Mar;52(3):386-91. doi: 10.1006/gyno.1994.1066. Gynecol Oncol. 1994. PMID: 8157196
-
Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.J Rheumatol. 1997 Apr;24(4):666-70. J Rheumatol. 1997. PMID: 9101499
-
New markers in serum for lymphocyte activation for predicting allograft rejection. Neopterin and soluble interleukin-2 receptor.Clin Lab Med. 1992 Mar;12(1):99-111. Clin Lab Med. 1992. PMID: 1563242 Review.
-
New immunologic markers for monitoring of cancer.Ann Chir Gynaecol. 1989;78(1):13-26. Ann Chir Gynaecol. 1989. PMID: 2667445 Review. No abstract available.
Cited by
-
Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma.Am J Clin Oncol. 2017 Apr;40(2):207-213. doi: 10.1097/COC.0000000000000124. Am J Clin Oncol. 2017. PMID: 25286079 Free PMC article.